Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00520767|
Recruitment Status : Active, not recruiting
First Posted : August 27, 2007
Results First Posted : March 30, 2015
Last Update Posted : February 22, 2019
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease.
PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients with primary amyloidosis or light chain deposition disease.
|Condition or disease||Intervention/treatment||Phase|
|Primary Systemic Amyloidosis Light Chain Deposition Disease||Drug: bortezomib Drug: dexamethasone Drug: melphalan Genetic: microarray analysis Other: flow cytometry Other: laboratory biomarker analysis Procedure: quality-of-life assessment||Phase 2|
- Determine the complete hematologic response rate at 12 months.
- Determine the overall hematologic response rate.
- Determine the organ response rate.
- Determine time to treatment failure.
- Assess toxicity of the regimen, in terms of incidence and severity of treatment-emergent peripheral neuropathy and quality of life.
- Determine the overall survival.
OUTLINE: This is a multicenter study.
Patients receive oral melphalan on days 1-4, bortezomib IV on days 1, 8, 15, and 22, and dexamethasone orally or IV on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment repeats every 4-6 weeks for up to 20 courses in the absence of disease progression or unacceptable toxicity.
Blood, urine, and bone marrow aspirates are collected at baseline and periodically after treatment to permit the correlation of clinical results with measured molecular events. A single baseline peripheral blood DNA sample is collected for future association studies linking disease onset, progression, and response to administered therapy with single nucleotide polymorphisms. Blood plasma and urine samples are evaluated for proteomic markers associated with disease progression and therapeutic response. Peripheral blood RNA samples are evaluated for transcriptional response to treatment of peripheral blood lymphocytes. Bone marrow aspirates are collected to extract plasma cells by flow cytometry for gene expression profiling.
Quality of life is assessed at the beginning of each course.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients With Symptomatic AL-Amyloidosis or Light Chain Deposition Disease|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||October 2010|
|Estimated Study Completion Date :||June 2019|
Experimental: Melphalan, Dexamethasone, Bortezomib,
Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
Other Name: Velcade
Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
Melphalan 9 mg/m2/day days 1-4
Genetic: microarray analysis
≤28 days prior to enrollment
Other: flow cytometry
Day 1 of cycles 6, 12, 18 and at end of study.
Other: laboratory biomarker analysis
≤28 days prior to enrollment
Procedure: quality-of-life assessment
Start of each cycle
- Complete Hematologic Response [ Time Frame: Up to 12 months ]
- Overall Survival [ Time Frame: Day 1 of Each Cycle and every 12 weeks after last treatment cycle ]
- Time to Treatment Failure [ Time Frame: Day 1 of Each Cycle ]
- Change in Quality of Life From Baseline as Assessed by the Functional Assessment of Cancer Therapy-Neurotoxicity Questionnaire. [ Time Frame: At the start of each cycle ]
- Organ Response Rate (OrR) [ Time Frame: Beginning of cycles 4, 8, 12, 16 and 20, at follow up and end of study. ]
- Toxicity, Including Neurotoxicity [ Time Frame: Day 1 of Each Cycle ]
- Overall Hematologic Response Rate (OHR) [ Time Frame: Beginning of cycles 4, 8, 12, 16 and 20, at follow up and end of study. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00520767
|United States, Colorado|
|Rocky Mountain Cancer Centers/Rocky Mountain Blood & Marrow Transplant Program|
|Denver, Colorado, United States, 80218|
|United States, Massachusetts|
|Boston University Cancer Research Center|
|Boston, Massachusetts, United States, 02118|
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Josephine Ford Cancer Center at Henry Ford Hospital|
|Detroit, Michigan, United States, 48202|
|Providence Cancer Institute at Providence Hospital - Southfield Campus|
|Southfield, Michigan, United States, 48075|
|United States, North Carolina|
|Duke Comprehensive Cancer Center|
|Durham, North Carolina, United States, 27710|
|United States, Pennsylvania|
|UPMC Cancer Centers|
|Pittsburgh, Pennsylvania, United States, 15232|
|Principal Investigator:||Jeffrey A. Zonder, MD||Barbara Ann Karmanos Cancer Institute|